A Single-Center, Randomized, Double-Blind, 3-Treatment, 3-Period, 6-Sequence Cross-Over Study To Compare The Pharmacokinetic And Pharmacodynamic Effects of Single Doses of Insulin Glargine Given As U200 And U500 To Lantus(R) In A Euglycemic Clamp Setting In Subjects With Type 1 Diabetes
Phase of Trial: Phase I
Latest Information Update: 30 Dec 2014
Price : $35 *
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Sanofi
- 23 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 30 Jul 2014 Planned End Date changed from 1 Oct 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.